ClinicalTrials.gg
Active, not recruitingNCT07051473Updated Feb 25, 2026

Relationship Between Coronary CT Angiography Findings and Prognosis Of Patients Undergoing PCI

An observational study in Coronary Artery Disease, sponsored by Istanbul University - Cerrahpasa. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Istanbul University - Cerrahpasa · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Coronary Artery Disease with a site in Turkey — 34 open to participants now, 43 under way, 4 of them phase 3. Coronary Artery Disease · Turkey.

Planned enrollment
21st of 66
300 · median 167
Started
2024
with 17 others
Observational
66 of 139
15 open now
Primary completion
2026-12
later than 20 of 42 live
Registered
96th of 139
by date
Lead sponsor
5 of 139
Istanbul University - Cerrahpasa

Among the 139 studies in Coronary Artery Disease with a site in Turkey, this one is the 21st largest by planned enrollment of the 66 observational ones that give a count, is one of 18 that started in 2024, is one of 66 observational ones, reaches primary completion later than 20 of the 42 other live ones, and was the 96th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

34 of the 139 studies in Coronary Artery Disease with a site in Turkey are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Coronary Artery Disease with a site in Turkey, or all of them as a file.
02

Study summary

Researchers at Cerrahpaşa Medical School in Istanbul are studying how a heart imaging test called coronary CT angiography can help improve care for people with coronary artery disease. This disease happens when fatty buildups, known as plaques, form in the arteries that supply blood to the heart. Over time, these plaques can limit blood flow and lead to serious problems like heart attacks. The goal of this research is to better understand which types of plaques may lead to worse outcomes, and how treatment choices-such as placing a stent or using medication-can affect a person's long-term heart health. This study will help doctors make better treatment decisions in the future. Some plaques are more dangerous than others, even when they don't cause major blockages. These are called high-risk or "vulnerable" plaques. Even though they may not narrow the artery much at first, they can still cause heart attacks in the future. Currently, doctors do not usually place stents in arteries unless the plaque causes a serious blockage. This is because stenting also carries risks, and it is not clear whether treating high-risk plaques early-before they cause problems-helps people live longer or feel better. This study hopes to find out whether certain types of plaques should be treated differently in the future. This study will include at least 789 adults who have already had coronary CT angiography as part of their regular care at Cerrahpaşa Medical School's cardiology clinic. These participants were treated either with a stent or with medication, depending on their medical needs. The decision to do the scan and how to treat the person was made by their doctor, following national and international medical guidelines. People who join the study do so voluntarily. They can choose to leave the study at any time without affecting their regular medical care. Participants will be followed for at least one year, starting from the day of their CT scan. They will return for check-ups at 3, 6, and 12 months. After the first year, they will continue to have yearly follow-up visits as part of routine care. At each visit, the study team will check symptoms, such as chest pain or shortness of breath; monitor health indicators, like cholesterol and blood sugar; and review any new heart procedures or treatments. Researchers will also review results from medical tests, such as blood tests, electrocardiograms (EKGs), heart ultrasounds (echocardiograms), repeat heart scans or procedures if done. If a participant has had a heart procedure done at another hospital, they will be asked to bring those records to their next appointment. This helps the research team get a full picture of each participant's heart health. The researchers will look at the features of the plaques seen in each participant's heart scan. They want to find out which types of plaques are more likely to lead to heart attacks or other serious problems. Participants will be divided into groups based on whether they received a stent or not. The researchers will compare outcomes between these groups to see if certain plaque types are more dangerous and whether stenting made a difference. The study will try to answer questions like: which plaque features are linked to future heart problems; do people with high-risk plaques do better with stents or with medication; can doctors use plaque features to decide who should get a stent? This research may help doctors better identify high-risk plaques and choose the right treatment for each person. The study does not involve any new, experimental, or unapproved treatments. All participants will receive medical care that follows well-established guidelines from groups like the European Society of Cardiology (ESC) and the American Heart Association (AHA). Participants are not asked to take new medications or undergo any tests or treatments that are not already part of their usual care. If new medical knowledge becomes available during the study that could affect treatment, participants will be informed and can choose whether to continue with the original plan or make changes. All personal and medical information will be kept confidential. The data will be stored securely in the hospital's system, and only the research team and authorised health officials will be allowed to access it. Participants' names and other identifying information will not appear in any published reports. If a participant wants to know their results or the overall results of the study, they can ask for a report. Even if someone leaves the study or stops coming to the clinic, the information already collected may still be used in the research unless the participant requests otherwise. There is no cost to participate in this study. The study will not affect your health insurance or create any additional charges. All medical care will continue to be covered by Turkey's national health system or your existing insurance.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Coronary artery disease
  • Vulnerable plaque
  • Vulnerable patient
  • Vulnerable blood
  • High risk coronary plaques
  • PCI
  • Coronary intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population consists of individuals residing in the Republic of Turkey. The study sample was selected using a simple random sampling method and includes individuals from this population who presented to the Cardiology Department of Cerrahpaşa Medical Faculty with symptoms or findings suggestive of stable coronary artery disease. It is assumed that every citizen living within the borders of the Republic of Turkey has an equal probability of presenting to the clinic with complaints related to this condition.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be over 18 years of age.
  2. Have presented to the Cardiology Department of Cerrahpaşa Medical Faculty with symptoms or findings suggestive of stable coronary artery disease and undergone a coronary CT angiography based on clinical evaluation.
  3. In addition, meet at least one of the following conditions:

    • The coronary CT angiography showed at least one lesion with at least one high-risk plaque feature, and based on the 2018 European Society of Cardiology (ESC) Guidelines on Myocardial Revascularisation and the presence of CAD-RADS 1 or 2 lesions, no revascularisation was performed.
    • The coronary CT angiography revealed a CAD-RADS 3 or higher lesion without high-risk plaque features, and revascularisation was performed on the target lesion, in accordance with the 2018 European Society of Cardiology (ESC) Guidelines on Myocardial Revascularisation.
    • The coronary CT angiography revealed a CAD-RADS 3 or higher lesion with high-risk plaque features, and revascularisation was performed on the target lesion, in accordance with the 2018 European Society of Cardiology (ESC) Guidelines on Myocardial Revascularisation.

Exclusion criteria

Exclusion Criteria:

  • Being underaged (below 18 years of age).
  • Loss of medical follow-up data caused by discontinuation of participation in follow-up visits.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • High risk plaque features positive, PCI positive

    The people that has at least one lesion in their coronary arteries, carrying at least one high-risk plaque feature, derived from CCTA and treated with PCI of that lesion

  • High risk plaque features positive, PCI negative

    The people that has at least one lesion in their coronary arteries, carrying at least one high-risk plaque feature, derived from CCTA and not treated with PCI of that lesion

  • High-risk plaque features negative, PCI positive

    The people that has no lesion in their coronary arteries, carrying at least one high-risk plaque feature, derived from CCTA and treated with PCI of any lesion

06

What researchers measure

Primary outcomes

  1. All cause death

    Death from any cause

    Time frame: Baseline, 3 months, 6 months, 12 months

  2. Major adverse cardiovascular events

    Composition of cardiac death, spontaneous myocardial infarction, target vessel myocardial infarction, target vessel revascularisation, target lesion revascularisation

    Time frame: Baseline, 3 months, 6 months, 12 months

Secondary outcomes

  1. Any myocardial infarction

    Any event of myocardial infarction defined by the "Fourth Universal Definition Of Myocardial Infarction"

    Time frame: Baseline, 3 months, 6 months, 12 months

  2. Any revascularisation procedure

    Revascularisation by either percutaneous coronary intervention or coronary artery bypass grafting

    Time frame: Baseline, 3 months, 6 months, 12 months

  3. Target vessel non-target lesion revascularisation

    Any lesion or revascularisation of a lesion in the target vessel other than the target lesion, respectively

    Time frame: Baseline, 3 months, 6 months, 12 months

  4. Non-target vessel revascularisation

    Revascularisation of a vessel for which revascularisation is not attempted in the first place, or of one with no lesion with high-risk plaque characteristics.

    Time frame: Baseline, 3 months, 6 months, 12 months

  5. Improvement in angina class as defined by the Canadian Cardiovascular Society (CCS)

    Any improvement in the angina class of the Canadian Cardiovascular Society (CCS) from a higher class to a lower class

    Time frame: Baseline, 3 months, 6 months, 12 months

Other outcomes

  1. Procedural success

    Achievement of \< 30 % residual diameter stenosis of the target lesion assessed by visual inspection or QCA and no in-hospital major adverse cardiac events (MACE, a composite of death, MI, or repeat coronary revascularisation of the target lesion).

    Time frame: At the end of percutaneous coronary intervention procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All IPD collected throughout the trial

Supporting information: Study protocol, Informed consent form

Time frame: Starting from the publication of results and earning of the 1 year of publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 24 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 4, 2025
StartActual
Dec 1, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07051473
Responsible party
Alpin Mert TEKİN (Research Assistant, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Jul 4, 2025
Start date
Dec 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 25, 2026

Study contacts

Barış İKİTİMUR
study director · İstanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion